Literature DB >> 8411025

Prenatal screening for cystic fibrosis: psychological effects on carriers and their partners.

M E Mennie1, M E Compton, A Gilfillan, W A Liston, I Pullen, D A Whyte, D J Brock.   

Abstract

This study aimed to assess the psychological impact of screening for cystic fibrosis (CF) carrier status in a population of pregnant women. A cohort of 1798 women, who accepted the offer of testing before 18 weeks of pregnancy, filled in a self administered questionnaire seeking information on their perceived risk of carrier status and their emotional response, as well as a general health questionnaire (GHQ). Sixty-four women identified as CF carriers had partners who received a negative test result. This group and their partners were assessed, together with selected controls, on four further occasions: (1) on receiving the carrier's positive test result; (2) on receiving the partner's negative test result; (3) six weeks later; (4) six weeks after delivery. The instruments used were the GHQ and the Symptom Rating Test (SRT). When compared to control subjects, carriers showed a significant increase in generalised psychological disturbance which could be attributed specifically to symptoms of anxiety and depression during the period (average four days) that they awaited their partner's test result. On receiving a partner's negative test result, the carriers returned to control levels and maintained this equilibrium. Although there was no significant difference in generalised psychological disturbance between partners and their selected controls, partners did become significantly more anxious and manifested feelings of inadequacy while awaiting their own test result. Both male partners and male control subjects were more likely to become anxious if their partner was distressed.

Entities:  

Mesh:

Year:  1993        PMID: 8411025      PMCID: PMC1016452          DOI: 10.1136/jmg.30.7.543

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  8 in total

1.  Design of diagnostic tests for congenital and acquired colour vision defects.

Authors:  J Birch-Cox
Journal:  Mod Probl Ophthalmol       Date:  1976

2.  Color matching and foveal densitometry in patients and carriers of an X-linked progressive cone dystrophy.

Authors:  J E Keunen; J A van Everdingen; L N Went; J A Oosterhuis; D van Norren
Journal:  Arch Ophthalmol       Date:  1990-12

3.  Dominant cone dystrophy starting with blue cone involvement.

Authors:  M J van Schooneveld; L N Went; J A Oosterhuis
Journal:  Br J Ophthalmol       Date:  1991-06       Impact factor: 4.638

4.  Increment spectral sensitivity of hemizygotes and heterozygotes for different classes of colour vision.

Authors:  E C de Vries-de Mol; L N Went; D van Norren; L C Pols
Journal:  Mod Probl Ophthalmol       Date:  1978

5.  Cone dystrophy, nyctalopia, and supernormal rod responses. A new retinal degeneration.

Authors:  P Gouras; H M Eggers; C J MacKay
Journal:  Arch Ophthalmol       Date:  1983-05

6.  New test for the detection of tritan defects evaluated in two surveys.

Authors:  D van Norren; L N Went
Journal:  Vision Res       Date:  1981       Impact factor: 1.886

7.  An electroretinographic and molecular genetic study of X-linked cone degeneration.

Authors:  E Reichel; A M Bruce; M A Sandberg; E L Berson
Journal:  Am J Ophthalmol       Date:  1989-11-15       Impact factor: 5.258

8.  The genetics of tritan disturbances.

Authors:  L N Went; N Pronk
Journal:  Hum Genet       Date:  1985       Impact factor: 4.132

  8 in total
  15 in total

1.  Genetic counseling: the impact in Indian milieu.

Authors:  Shubha R Phadke; Amita Pandey; Ratna Dua Puri; S J Patil
Journal:  Indian J Pediatr       Date:  2004-12       Impact factor: 1.967

2.  Evaluating genetic counseling: client expectations, psychological adjustment and satisfaction with service.

Authors:  Angela Davey; Kristie Rostant; Karen Harrop; Jack Goldblatt; Peter O'Leary
Journal:  J Genet Couns       Date:  2005-06       Impact factor: 2.537

3.  Cystic fibrosis carrier population screening in the primary care setting.

Authors:  S Loader; P Caldwell; A Kozyra; J C Levenkron; C D Boehm; H H Kazazian; P T Rowley
Journal:  Am J Hum Genet       Date:  1996-07       Impact factor: 11.025

4.  Attitudes of potential providers towards preconceptional cystic fibrosis carrier screening.

Authors:  Francis A M Poppelaars; Herman J Adèr; Martina C Cornel; Lidewij Henneman; Rosella P M G Hermens; Gerrit van der Wal; Leo P ten Kate
Journal:  J Genet Couns       Date:  2004-02       Impact factor: 2.537

5.  Threat to Parental Role: A Possible Mechanism of Altered Self-Concept Related to Carrier Knowledge.

Authors:  A McConkie-Rosell; B M DeVellis
Journal:  J Genet Couns       Date:  2000-08       Impact factor: 2.537

6.  Attitudes of health care professionals toward carrier screening for cystic fibrosis. A review of the literature.

Authors:  S Janssens; A De Paepe; P Borry
Journal:  J Community Genet       Date:  2012-12-29

7.  PCR-based screening for cystic fibrosis carrier mutations in an ethnically diverse pregnant population.

Authors:  W W Grody; C Dunkel-Schetter; Z H Tatsugawa; M A Fox; C Y Fang; R M Cantor; J M Novak; H N Bass; B F Crandall
Journal:  Am J Hum Genet       Date:  1997-04       Impact factor: 11.025

8.  The uptake and acceptability to patients of cystic fibrosis carrier testing offered in pregnancy by the GP.

Authors:  N E Hartley; D Scotcher; H Harris; P Williamson; A Wallace; D Craufurd; R Harris
Journal:  J Med Genet       Date:  1997-06       Impact factor: 6.318

9.  Patient actions and reactions after receiving negative results from expanded carrier screening.

Authors:  S A Kraft; J L Schneider; M C Leo; T L Kauffman; J V Davis; K M Porter; C K McMullen; B S Wilfond; K A B Goddard
Journal:  Clin Genet       Date:  2018-03-13       Impact factor: 4.438

10.  Acceptability of carrier screening for cystic fibrosis during pregnancy in a German population.

Authors:  U Jung; U Urner; K Grade; C Coutelle
Journal:  Hum Genet       Date:  1994-07       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.